Working… Menu

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00248144
Recruitment Status : Completed
First Posted : November 3, 2005
Last Update Posted : December 10, 2007
Information provided by:

Brief Summary:
The study is designed to assess the efficacy and safety of patient-initiated therapy with famciclovir 1500 mg o.d. or 750 mg b.i.d. for one day treatment in adult men and women with recurrent herpes labialis

Condition or disease Intervention/treatment Phase
Recurrent Herpes Labialis Drug: Famciclovir Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-Blinded Controlled Study to Compare the Effectiveness of a Single Dose (1500 mg) of Famciclovir, One Day (750 mg q12) of Famciclovir and Placebo in Patient-Initiated Episodic Treatment of Recurrent Herpes Labialis
Study Start Date : October 2003
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cold Sores
Drug Information available for: Famciclovir

Primary Outcome Measures :
  1. Time to healing of the primary lesion complex (loss of crust from vesicular [classical] lesions)

Secondary Outcome Measures :
  1. safety and tolerability assessed by adverse events (AEs)
  2. resolution of pain / discomfort after short-course regimens
  3. proportion of patients with aborted lesions
  4. time to healing of all vesicular lesions
  5. time to healing of all aborted (non-vesicular) lesions

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients aged 18 years or older
  • A history typical for recurrent herpes labialis. The subject must have experienced three or more episodes of cold sores in the last 12 months, and have a history of prodromal symptoms, as defined by the patient, preceding at least 50% of these cold sores, and must also have a history of vesicular lesions in at least 50% of the recurrent episodes of cold sores.
  • General good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's account of his/her medical history
  • Women of child bearing potential had to use an accepted method of birth control (surgical sterilization; intra-uterine contraceptive device; oral contraceptives; hormone delivery systems such as Norplant® or Depo-Provera injections; a diaphragm in combination with contraceptive cream, jelly, or foam; or a condom in combination with contraceptive cream, jelly or foam). Patients unable or unwilling to use one of the methods of birth control listed above for the duration of the study could not enter the study.
  • For women of child-bearing potential, a negative pregnancy test (urine) at screening was required
  • Signature on the informed consent document

Exclusion Criteria:

  • Previous herpes vaccination
  • Patients using topical immunosuppressive agents (including steroids, tacrolimus and pimecrolimus) on or near the face or systemic immunosuppressive agents (including steroids, tacrolimus and pimecrolimus) within 30 days of screening
  • Patients known to be immunosuppressed due to underlying disease (e.g. HIV infection) or concomitant treatment (e.g. cancer chemotherapy)
  • Recent history of alcohol or drug abuse, which in the opinion of the investigator, could interfere with that study patient's compliance with study requirements
  • Significant skin disease such as atopic dermatitis or eczema that would interfere with the assessment of lesions
  • Allergy or hypersensitivity to formulations containing acyclovir, penciclovir, famciclovir, and/or other nucleoside analogues
  • Women who were lactating or breast feeding
  • Had already been randomized once into the study
  • Patients who had received an investigational drug in the past four weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00248144

Sponsors and Collaborators
Layout table for investigator information
Study Chair: Novartis Pharmaceuticals Japan Novartis Pharmaceuticals

Layout table for additonal information Identifier: NCT00248144     History of Changes
Other Study ID Numbers: CFAM810A2403
First Posted: November 3, 2005    Key Record Dates
Last Update Posted: December 10, 2007
Last Verified: August 2006
Keywords provided by Novartis:
Herpes labialis
Additional relevant MeSH terms:
Layout table for MeSH terms
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases
Antiviral Agents
Anti-Infective Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action